{"id":"https://openalex.org/W7223108385","doi":"https://doi.org/10.1016/j.htct.2026.107854","title":"COMPARATIVE EFFECTIVENESS OF TECLISTAMAB VS REAL-WORLD PHYSICIAN\u2019S CHOICE OF CARFILZOMIB-AND/OR POMALIDOMIDE-BASED REGIMENS IN LOCOMMOTION AND MOMMENT IN TCE RRMM","display_name":"COMPARATIVE EFFECTIVENESS OF TECLISTAMAB VS REAL-WORLD PHYSICIAN\u2019S CHOICE OF CARFILZOMIB-AND/OR POMALIDOMIDE-BASED REGIMENS IN LOCOMMOTION AND MOMMENT IN TCE RRMM","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7223108385","doi":"https://doi.org/10.1016/j.htct.2026.107854"},"language":"en","primary_location":{"id":"doi:10.1016/j.htct.2026.107854","doi":"https://doi.org/10.1016/j.htct.2026.107854","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107854","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016019/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016019/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5159220417","display_name":"Maria-victoria MATEOS","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184999862","display_name":"Universidad de Salamanca","ror":"https://ror.org/02f40zc51","country_code":"ES","type":"education","lineage":["https://openalex.org/I184999862"]},{"id":"https://openalex.org/I4210134045","display_name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","ror":"https://ror.org/03em6xj44","country_code":"ES","type":"facility","lineage":["https://openalex.org/I184999862","https://openalex.org/I4210099034","https://openalex.org/I4210134045"]},{"id":"https://openalex.org/I4210138819","display_name":"Centro de Investigaci\u00f3n del C\u00e1ncer","ror":"https://ror.org/04rxrdv16","country_code":"ES","type":"facility","lineage":["https://openalex.org/I134820265","https://openalex.org/I184999862","https://openalex.org/I4210138819"]},{"id":"https://openalex.org/I4388891778","display_name":"Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer de Salamanca","ror":"https://ror.org/043vr8e29","country_code":"ES","type":"facility","lineage":["https://openalex.org/I134820265","https://openalex.org/I184999862","https://openalex.org/I4388891778"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Mar\u0131a-victoria MATEOS","raw_affiliation_strings":["University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain","institution_ids":["https://openalex.org/I184999862","https://openalex.org/I4210134045","https://openalex.org/I4210138819","https://openalex.org/I4388891778"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159213840","display_name":"Katja WEISEL","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108711","display_name":"University Medical Center Hamburg-Eppendorf","ror":"https://ror.org/01zgy1s35","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I159176309","https://openalex.org/I4210108711"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Katja WEISEL","raw_affiliation_strings":["University Medical Center of Hamburg-Eppendorf, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Medical Center of Hamburg-Eppendorf, Hamburg, Germany","institution_ids":["https://openalex.org/I4210108711"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028729741","display_name":"Francesca Ghilotti","orcid":"https://orcid.org/0000-0002-7978-376X","observed_orcids":["https://orcid.org/0000-0002-7978-376X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Francesca GHILOTTI","raw_affiliation_strings":["HTA Analytics, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HTA Analytics, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014103994","display_name":"Joris Diels","orcid":"https://orcid.org/0000-0002-9456-9120","observed_orcids":["https://orcid.org/0000-0002-9456-9120"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joris DIELS","raw_affiliation_strings":["Johnson & Johnson, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson, Belgium","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159204767","display_name":"Pamela VILLANOVA","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160666","display_name":"Johnson & Johnson (Brazil)","ror":"https://ror.org/04f89zf73","country_code":"BR","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210160666"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Pamela VILLANOVA","raw_affiliation_strings":["Johnson & Johnson Brazil, S\u00e3o Paulo, SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Brazil, S\u00e3o Paulo, SP, Brazil","institution_ids":["https://openalex.org/I4210160666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5119658973","display_name":"Anielle Jacomini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160666","display_name":"Johnson & Johnson (Brazil)","ror":"https://ror.org/04f89zf73","country_code":"BR","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210160666"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Anielle JACOMINI","raw_affiliation_strings":["Johnson & Johnson Brazil, S\u00e3o Paulo, SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Brazil, S\u00e3o Paulo, SP, Brazil","institution_ids":["https://openalex.org/I4210160666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5119658974","display_name":"Simone Forny","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160666","display_name":"Johnson & Johnson (Brazil)","ror":"https://ror.org/04f89zf73","country_code":"BR","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210160666"]}],"countries":["BR"],"is_corresponding":false,"raw_author_name":"Simone FORNY","raw_affiliation_strings":["Johnson & Johnson Brazil, S\u00e3o Paulo, SP, Brazil"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Brazil, S\u00e3o Paulo, SP, Brazil","institution_ids":["https://openalex.org/I4210160666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159213216","display_name":"Monserrat ROJAS","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Monserrat ROJAS","raw_affiliation_strings":["Johnson & Johnson Mexico, Mexico"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Mexico, Mexico","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009664468","display_name":"Mary Slavcev","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145932","display_name":"Johnson & Johnson (Canada)","ror":"https://ror.org/04z0qye94","country_code":"CA","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4210145932"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Mary SLAVCEV","raw_affiliation_strings":["Johnson & Johnson Canada, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson Canada, Canada","institution_ids":["https://openalex.org/I4210145932"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016448823","display_name":"Marguerite O\u2019Hara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330063522","display_name":"Johnson & Johnson (United States)","ror":"https://ror.org/03qd7mz70","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marguerite O'HARA","raw_affiliation_strings":["Johnson & Johnson United States, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johnson & Johnson United States, United States","institution_ids":["https://openalex.org/I1330063522"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5048045002","display_name":"Philippe Moreau","orcid":"https://orcid.org/0000-0002-2868-7401","observed_orcids":["https://orcid.org/0000-0002-2868-7401"]},"institutions":[{"id":"https://openalex.org/I4210133078","display_name":"H\u00f4tel-Dieu de Paris","ror":"https://ror.org/03jmjy508","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210124464","https://openalex.org/I4210133078"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Philippe MOREAU","raw_affiliation_strings":["University Hospital H\u00f4tel-Dieu, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital H\u00f4tel-Dieu, France","institution_ids":["https://openalex.org/I4210133078"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":0,"currency":"USD","value_usd":0},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.78454134,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"48","issue":null,"first_page":"107854","last_page":"107854"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/teclistamab","display_name":"teclistamab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9539999961853027},{"id":"https://openalex.org/keywords/triple-class-exposed-myeloma","display_name":"triple-class exposed myeloma","score":0.781000018119812},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":0.8730000257492065},{"id":"https://openalex.org/keywords/pomalidomide","display_name":"pomalidomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.628000020980835},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.765999972820282},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9760000109672546},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7910000085830688},{"id":"https://openalex.org/keywords/time-to-next-treatment","display_name":"time to next treatment","score":0.6150000095367432},{"id":"https://openalex.org/keywords/majestec-1","display_name":"MajesTEC-1","score":0.9869999885559082}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9659000039100647},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4311999976634979},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40209999680519104},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.34929999709129333},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.25760000944137573},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.18870000541210175},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.1551000028848648},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.1492999941110611},{"id":"https://openalex.org/C2983635472","wikidata":"https://www.wikidata.org/wiki/Q334911","display_name":"Health insurance","level":3,"score":0.1446000039577484},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.13330000638961792}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/j.htct.2026.107854","doi":"https://doi.org/10.1016/j.htct.2026.107854","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107854","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016019/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:a66443f35ba844a9bcebf45a56176685","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/a66443f35ba844a9bcebf45a56176685","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Hematology, Transfusion and Cell Therapy, Vol 48, Iss , Pp 107854- (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1016/j.htct.2026.107854","doi":"https://doi.org/10.1016/j.htct.2026.107854","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.htct.2026.107854","pdf_url":"https://www.sciencedirect.com/science/article/pii/S2531137926016019/pdf","source":{"id":"https://openalex.org/S2898598332","display_name":"Hematology Transfusion and Cell Therapy","issn_l":"2531-1379","issn":["2531-1379","2531-1387"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","ki-jl-1","poland-20","russia-white-list-3","scielo"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hematology, Transfusion and Cell Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332194","display_name":"Johnson and Johnson","ror":"https://ror.org/03qd7mz70"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223108385.pdf","grobid_xml":"https://content.openalex.org/works/W7223108385.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389902541","https://openalex.org/W4360806629","https://openalex.org/W7154496278","https://openalex.org/W4281672072","https://openalex.org/W4283714474","https://openalex.org/W4281644891","https://openalex.org/W4323045882","https://openalex.org/W4390126993","https://openalex.org/W7162551469","https://openalex.org/W4386071019"],"abstract_inverted_index":{"Background":[0],"A":[1],"pooled":[2,84,99,272],"analysis":[3,100],"from":[4,97,174,269],"the":[5,270,300,319],"prospective,":[6],"noninterventional,":[7],"multinational":[8],"LocoMMotion":[9,81,102],"(NeT04035226)":[10],"and":[11,33,82,107,112,163,168,190,205,252,285,317],"MoMMent":[12,83,108],"(NeT05160584)":[13],"studies":[14],"demonstrated":[15,277,295],"suboptimal":[16],"outcomes":[17,64],"in":[18,53,70,80,139,222,227,267,281,313,324],"patients":[19,54,66,116,233,325],"with":[20,31,55,72,75,114,159,220,246,258,263,304,326],"triple-class":[21],"exposed":[22],"(TCE)":[23],"relapsed/refractory":[24],"multiple":[25],"myeloma":[26],"(RRMM),":[27],"even":[28],"when":[29],"treated":[30,74,115,219,262,303],"carfilzomib":[32,76,264,305],"pomalidomide":[34,266],"regimens.":[35],"MajesTEC-1":[36,71,119,223],"(NCT04557098)":[37],"is":[38],"a":[39,46,98],"single-arm":[40],"phase":[41],"1/2":[42],"study":[43],"evaluating":[44],"teclistamab,":[45],"B-cell":[47],"maturation":[48],"antigen\u00d7CD3":[49],"(BCMA)":[50],"bispecific":[51],"antibody":[52],"RRMM":[56],"who":[57,67,117],"are":[58],"TCE.":[59],"Here,":[60],"we":[61],"compared":[62,113,257,298],"efficacy":[63,230],"of":[65,101,153,197],"received":[68],"teclistamab":[69,154],"those":[73],"and/or":[77,265,306],"pomalidomide-based":[78,307],"regimens":[79],"analysis.":[85],"Methods":[86],"An":[87],"external":[88],"control":[89],"arm":[90],"(Real-World":[91],"Physician\u2019s":[92],"Choice":[93],"(RWPC)":[94],"was":[95,133,157,183],"created":[96],"(clinical":[103,109],"cut-off:":[104,110,127],"Oct":[105],"22)":[106],"Aug24":[111],"met":[118],"eligibility":[120],"criteria":[121],"(teclistamab":[122],"1.5":[123],"mg/kg":[124],"weekly;":[125],"clinical":[126,311],"Aug":[128],"2023).":[129],"Inverse":[130],"probability":[131],"weighting":[132],"used":[134,184],"to":[135,185,239,299,321],"adjust":[136],"for":[137,193],"imbalances":[138],"baseline":[140,212],"covariates.":[141],"For":[142],"binary":[143],"endpoints":[144,195],"such":[145],"as":[146],"overall":[147,206],"response":[148,165,198],"rate":[149,166],"(ORR),":[150],"relative":[151,164],"effect":[152],"versus":[155],"RWPC":[156,268,291,301],"estimated":[158],"an":[160],"odds":[161],"ratio":[162],"(RR)":[167],"95%":[169,191],"confidence":[170],"interval":[171],"(CI),":[172],"derived":[173],"weighted":[175],"logistic":[176],"regression.":[177],"Weighted":[178],"Cox":[179],"proportional":[180],"hazards":[181],"model":[182],"estimate":[186],"hazard":[187],"ratios":[188],"(HR)":[189],"CIs":[192],"time-to-event":[194],"[duration":[196],"(DOR),":[199],"progression-free":[200],"survival":[201,207],"(PFS),":[202],"time-to-next-treatment":[203],"(TTNT)":[204],"(OS)].":[208],"Results":[209],"After":[210],"reweighting,":[211],"characteristics":[213],"were":[214,234],"balanced":[215],"across":[216],"cohorts.":[217],"Patients":[218],"Teclistamab":[221,276,294],"had":[224],"significant":[225,279],"improvements":[226,280],"all":[228],"evaluated":[229],"outcomes.":[231],"Teclistamab-treated":[232],"almost":[235],"2-fold":[236],"more":[237],"likely":[238],"reach":[240],"ORR":[241],"(RR=2.10":[242],"(1.30":[243],"\u2013":[244],"3.40),":[245],"durable":[247],"responses":[248],"(DoR":[249],"HR=0.31":[250],"(0.19-0.53))":[251],"longer":[253],"TTNT":[254],"HR=0.48":[255],"(0.36-0.66)":[256],"eligibility-matched":[259],"patient":[260],"cohorts":[261],"LocoMMotion/MoMMent":[271],"dataset.":[273],"In":[274],"addition":[275],"statistically":[278],"PFS":[282],"HR=0.50":[283],"(0.36-0.68)":[284],"OS":[286],"HR=0.66":[287],"(0.47-0.93)":[288],"vs":[289],"this":[290],"subgroup.":[292],"Conclusion":[293],"improved":[296],"effectiveness":[297],"subgroup":[302],"regimens,":[308],"reinforcing":[309],"its":[310],"value":[312],"delaying":[314],"disease":[315],"progression":[316],"extending":[318],"time":[320],"subsequent":[322],"therapies":[323],"TCE":[327],"RRMM.":[328]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-22T00:00:00"}